title: Management of malignancy-related ascites.
abstract: A 65-year-old Polish immigrant named T. J. was diagnosed with metastatic colon cancer in January 2012 when he presented with obstructing sigmoid colon cancer and liver metastases. A diverting colostomy as well as biopsy of his liver metastases was performed and chemotherapy with FOLFOX (5-fluorouracil [5-FU], leucovorin, oxaliplatin) and bevacizumab was initiated. After three months, he transitioned to maintenance therapy with infusional 5-FU and bevacizumab until he progressed in August 2012. Oxaliplatin was reintroduced and he responded until he developed progressive neuropathy in November and his therapy was changed to FOLFIRI (5-FU, leucovorin, irinotecan) and bevacizumab. T. J. developed liver progression after three months and, because he was Kras wild type, irinotecan and panitumumab were initiated. Liver-directed therapy also was pursued and he underwent radioembolization with yittrium-90 followed by chemoembolization with irinotecan-eluded beads. At the time of these procedures, T. J.'s portal and hepatic venous systems were patent (i.e., no thrombosis or obstruction causing portal hypertension).
authors.affiliation: Gastrointestinal Oncology Division, John Theurer Cancer Center, Hackensack University Medical Center in New Jersey.
authors.forename: Anne Marie C
authors.initials: AM
authors.lastname: Flaherty
mesh_terms: D000368:Aged; D001201:Ascites / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications* / Q000556:secondary; D008297:Male